Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for an existing buprenorphine/naloxone combination product; this is a regulatory action, not a clinical efficacy or safety study.
FDA supplemental approval action establishing Risk Evaluation and Mitigation Strategy (REMS) requirements for buprenorphine hydrochloride sublingual tablets; does not report clinical trial outcomes.
FDA supplemental approval of a manufacturing/CMC change for an existing buprenorphine hydrochloride product; does not report clinical trial data or comparative efficacy.
This is an FDA supplemental approval action for a Risk Evaluation and Mitigation Strategy (REMS) modification to an existing buprenorphine product; it does not report clinical trial data or comparative efficacy.